Jon Cuthbert

Algorae Pharmaceuticals (ASX:1AI) has secured a $3 million receivables-based working capital facility with ScotPac Business Finance.

Telix Pharmaceuticals (ASX:TLX) reported strong commercial and operational performance for the quarter ended Dec. 31, 2025, achieving its upgraded full-year FY25 revenue guidance with unaudited group revenue of approximately US$804 million.

Corvus Pharmaceuticals (NASDAQ:CRVS) shares skyrocketed more than 60% in early trading Tuesday after the company reported that its experimental oral therapy significantly cleared skin in patients with moderate-to-severe atopic dermatitis.

MSC Income Fund (NYSE:MAIN) signaled a strong finish to 2025, providing preliminary fourth-quarter results that point to rising asset values and double-digit returns on equity as it navigates a stabilizing interest rate environment.

Dyne Therapeutics (NASDAQ:DYN) secured a regulatory win in Asia as Japanese authorities granted orphan drug status to its lead candidate for myotonic dystrophy, providing the biotech with a clear path toward market exclusivity in the world’s third-largest pharmaceutical market.

Novavax (NASDAQ:NVAX) shares rose in early trading after the company reached an agreement to license its vaccine-boosting technology to Pfizer (NYSE;PFE), providing a fresh source of capital for the Maryland-based biotech.

KeyCorp (NYSE:KEY) reported record full-year results for 2025, capped by a fourth quarter that saw net income climb to $474 million, or $0.43 per diluted share.

Mercantile Bank (NASDAQ:MBWM) reported a robust finish to fiscal year 2025, characterized by double-digit profit growth and the strategic expansion of its footprint across Michigan.

Piper Sandler (NYSE:PIPR) has completed its acquisition of MENA Growth Partners (MGP), an Abu Dhabi-based merchant bank, marking the Minneapolis-based firm’s formal entry into the Gulf Cooperation Council (GCC) region.

Bitcoin’s internal market signals are improving as sell pressure fades and spot trading volumes begin to recover.